FORT LAUDERDALE, Fla., Oct. 06, 2016 -- OmniComm Systems, Inc. (OmniComm) (OTCQX:OMCM), a global leading provider of clinical data management technology, today announced that Scientia Clinical Research, Australia’s newest and most advanced early phase clinical trial facility at the University of New South Wales in Sydney, Australia has selected OmniComm’s TrialOne clinic automation and eSource application. Scientia Clinical Research is the first purpose built early phase clinical trials center in Sydney, Australia. In addition to first-in-human and first-in-patient studies, the facility will also support later phase trials across a broad range of disciplines. TrialOne will standardize processes, improve business intelligence, ensure compliance, and achieve overall business transformation within its early phase research.
“Scientia Clinical Research believes TrialOne will deliver a competitive advantage in the early phase clinical trial space in Australia,” says Lisa Nelson, CEO at Scientia Clinical Research.
TrialOne is a browser-based bedside data collection technology specifically designed to automate the workflows and processes within early phase research clinics. TrialOne enables the automation of clinic data collection; standardizes recruiting; facilitates the collection of study data and sample tracking; reduces discrepancies inherent in paper-based applications; and ensures compliance.
TrialOne is the market leading eSource system for early phase research clinics addressing the following needs of this organization:
- Manage and optimize patient screening and recruitment
- Provide secure and fully validated eSource
- Implement protocol compliant workflows and data capture from subject bedside
- Deliver automated data capture from medical monitoring equipment and devices
- Streamline staff training and support records
- Provide integration with laboratory information management systems (LIMS) for lab orders and lab results processing
“We are extremely proud that Scientia Clinical Research selected TrialOne early phase clinic automation solution for their state of the art, purpose built clinical trial center. Scientia is OmniComm’s first customer in Australia and New Zealand. This represents a decisive step for OmniComm in its penetration of the early phase and clinical trials market in Australia. Having Scientia as a high profile, top level customer will aid OmniComm in its regional expansion, not only with TrialOne but with all our products,” says Wolf Ondracek, managing director and SVP for the APAC region at OmniComm. “We are extremely pleased to be partnering and working with such a world-class organization as Scientia Clinical Research.”
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,800 clinical trials. For more information, visit www.omnicomm.com.
Trademarks
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Dennis Constantinou OmniComm Systems, Inc. +1.954.473.1254 [email protected]


SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence
Instagram Outage Disrupts Thousands of U.S. Users
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 



